Steward Health Care System

Return to Results

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neo

new search

Trial Conditions
  • Estrogen Receptor-positive Breast Cancer
  • HER2-positive Breast Cancer
  • Progesterone Receptor-positive Breast Cancer
  • Stage IB Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
What is the purpose of this trial?

This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive, operable or locally advanced breast cancer. Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and radiation therapy with or without hormone therapy may be an effective treatment for hormone receptor-positive, HER2-positive, operable or locally advanced breast cancer.

Date & Status

Recruiting

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Female

Eligibility

Inclusion Criteria:

- Patients should have a life expectancy of at least 10 years, excluding their
diagnosis of breast cancer; (comorbid conditions should be taken into consideration,
but not the diagnosis of breast cancer)

- Women of reproductive potential must agree to use an effective non-hormonal method of
contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and
estrogen deprivation therapy) and for at least 6 months after the last dose of study
therapy

- Submission of tumor samples is required for all patients; the local pathology
department policy regarding release of tumor samples must be considered in the
screening process; patients whose tumor samples are located in a pathology department
that by policy will not submit any samples for research purposes should not be
approached for participation in the B-52 trial

- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines

- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1

- Clinical staging for the primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if
clinically node negative; if the regional lymph nodes are cN1 and cytologically or
histologically positive or if cN2-N3 with or without a biopsy, the primary breast
tumor can be cT0-T4

- The diagnosis of invasive adenocarcinoma of the breast must have been made by core
needle biopsy

- Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound,
and/or magnetic resonance imaging [MRI]) within 6 weeks prior to randomization; if
suspicious or abnormal, fine needle aspirate (FNA) or core biopsy is recommended,
also within 6 weeks prior to randomization; findings of these evaluations will be
used to determine the nodal status prior to randomization:

- Nodal status - negative

- Imaging of the axilla is negative

- Imaging is suspicious or abnormal but the FNA or core biopsy of the
questionable node(s) on imaging is negative

- Nodal status - positive

- FNA or core biopsy of the node(s) is cytologically or histologically
suspicious or positive

- Imaging is suspicious or abnormal but FNA or core biopsy was not performed

- Patients may be premenopausal or postmenopausal at the time of randomization; for
study purposes, postmenopausal is defined as:

- Age 56 or older with no spontaneous menses for at least 12 months prior to study
entry; or

- Age 55 or younger with no spontaneous menses for at least 12 months prior to
study entry (e.g., spontaneous or secondary to hysterectomy) and with a
documented estradiol level in the postmenopausal range according to local
institutional/laboratory standard; or

- Documented bilateral oophorectomy

- The tumor must have been determined to be HER2-postive as follows:

- Immunohistochemistry (IHC) 3+ or

- In situ hybridization (ISH)-positive (defined by ratio of HER2 to circulating
endothelial progenitors [CEP]17 >= 2.0 or HER2 gene copy number >= 6 per
nucleus)

- The tumor must have been determined to be estrogen receptor (ER) and/or progesterone
(PgR) positive assessed by current American Society of Clinical Oncology
(ASCO)/College of American Pathologist (CAP) guideline recommendations for hormone
receptor testing; patients with >= 1% ER or PgR staining by IHC are considered
positive

- Absolute neutrophil count (ANC) must be >= 1200/mm^3

- Platelet count must be >= 100,000/mm^3

- Hemoglobin must be >= 10 g/dL

- Total bilirubin must be =< upper limit of normal (ULN) for the lab unless the patient
has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar
syndrome involving slow conjugation of bilirubin

- Alkaline phosphatase must be =< 2.5 x ULN for the lab

- Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab

- Alkaline phosphatase and AST may not both be > the ULN; for example, if the alkaline
phosphatase is > the ULN but =< 2.5 x ULN, the AST must be =< the ULN; if the AST is
> the ULN but =< 1.5 x ULN, the alkaline phosphatase must be =< ULN; Note: If alanine
aminotransferase (ALT) is performed instead of AST (per institution's standard
practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must
be =< 1.5 x ULN

- Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the
study if liver imaging (computed tomography [CT], MRI, positron emission tomography
[PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not
demonstrate metastatic disease and the requirements are met

- Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone
pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan
performed within 6 weeks prior to randomization does not demonstrate metastatic
disease

- Within 6 weeks prior to randomization, the most recent serum creatinine must be =<
ULN or measured or calculated creatinine clearance must be > 60 mL/min

- Left ventricular ejection fraction (LVEF) assessment must be performed within 3
months prior to randomization; (LVEF assessment performed by 2-dimensional [2-D]
echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be
substituted based on institutional preferences); the LVEF must be >= 50% regardless
of the cardiac imaging facility's lower limit of normal; note: since the pre-entry
LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical
that this baseline study be an accurate assessment; if the baseline LVEF is > 65%,
the investigator is encouraged to have the accuracy of the initial LVEF result
confirmed and repeat the test if the accuracy is uncertain

Exclusion Criteria:

- FNA alone to diagnose the breast cancer

- Excisional biopsy or lumpectomy performed prior to randomization

- Surgical axillary staging procedure prior to randomization; pre-neoadjuvant therapy
sentinel node biopsy is not permitted

- Definitive clinical or radiologic evidence of metastatic disease; (chest imaging
[mandatory for all patients] and other imaging [if required] must have been performed
within 90 days prior to randomization)

- Synchronous bilateral invasive breast cancer

- Synchronous or previous contralateral invasive breast cancer; (patients with
synchronous and/or previous contralateral ductal carcinoma in situ [DCIS] or lobular
carcinoma in situ [LCIS] are eligible)

- Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS;
(patients with synchronous or previous ipsilateral LCIS are eligible)

- Treatment including radiation therapy (RT), chemotherapy, targeted therapy, or
endocrine therapy for the currently diagnosed breast cancer prior to randomization

- Previous endocrine therapy such as raloxifene or tamoxifen (or other selective
estrogen receptor modulator [SERM]) or an aromatase inhibitor for any malignancy

- Previous therapy with anthracycline, taxanes, carboplatin, trastuzumab, or other HER2
targeted therapies for any malignancy

- Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement
therapy, etc. (these patients are eligible if this therapy is discontinued prior to
randomization)

- History of non-breast malignancies (except for in situ cancers treated only by local
excision and basal cell and squamous cell carcinomas of the skin) within 5 years
prior to randomization

- Cardiac disease (history of and/or active disease) that would preclude the use of the
drugs included in the treatment regimens; this includes but is not confined to:

- Active cardiac disease:

- Angina pectoris that requires the use of anti-anginal medication;

- Ventricular arrhythmias except for benign premature ventricular
contractions;

- Supraventricular and nodal arrhythmias requiring a pacemaker or not
controlled with medication;

- Conduction abnormality requiring a pacemaker;

- Valvular disease with documented compromise in cardiac function; and

- Symptomatic pericarditis

- History of cardiac disease:

- Myocardial infarction documented by elevated cardiac enzymes or persistent
regional wall abnormalities on assessment of left ventricular (LV)
function;

- History of documented congestive heart failure (CHF); and

- Documented cardiomyopathy

- Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150
mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if
initiation or adjustment of BP medication lowers pressure to meet entry criteria)

- Active hepatitis B or hepatitis C with abnormal liver function tests

- Intrinsic lung disease resulting in dyspnea

- Poorly controlled diabetes mellitus

- Active infection or chronic infection requiring chronic suppressive antibiotics

- Patients known to be human immunodeficiency virus (HIV) positive with a baseline
cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of
acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking
anti-retroviral therapy that may have a potential overlapping toxicity with the study
therapy are not eligible

- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse
Events version 4.0 (CTCAE v4.0)

- Malabsorption syndrome, ulcerative colitis, resection of the stomach or small bowel,
or other disease significantly affecting gastrointestinal function

- Other non-malignant systemic disease that would preclude treatment with any of the
treatment regimens or would prevent required follow-up

- Conditions that would prohibit administration of corticosteroids

- Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day
methylprednisolone equivalent (excluding inhaled steroids)

- Known hypersensitivity to any of the study drugs or any of the ingredients or
excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl
alcohol

- Pregnancy or lactation at the time of study entry; (note: pregnancy testing must be
performed within 2 weeks prior to randomization according to institutional standards
for women of childbearing potential)

- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements

- Use of any investigational product within 30 days prior to randomization

Gender: Female
Steward Physician(s)
  • Mothaffar Rimawi
Facilities
  • Saint Anne's Hospital - Recruiting
Trial Interventions
Biological
  • trastuzumab
  • pertuzumab
Drug
  • docetaxel
  • carboplatin
  • goserelin acetate
  • aromatase inhibition therapy
Other
  • laboratory biomarker analysis
  • quality-of-life assessment
Procedure
  • therapeutic conventional surgery
Radiation
  • whole breast irradiation
For more information about this trial, contact

John L. Yang

Phone: (508) 674-5600


Physician Researcher

Investigator Name:

  • Mothaffar Rimawi

Other Information

Sponsor: National Cancer Institute (NCI)
Phase: Phase 3
Trial ID: NCT02003209
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions